Dr. Laviolette has made two amazing discoveries:
1) Mentanine®, Omega3 compounds + CBD isolate, non-psychotic formula (Provisional Patent filed) capable of acting on mental health issues inside the Central Nervous System “ CNS“ by crossing the Blood Brain Barrier (BBB), with a significant increase of efficacy, while reducing dosage and;
2) Mentabinol®, THC + L-Theanine formulation (International Patent filed) as a safer alternative to all other THC products, addressing anxiety, depression, schizophrenia and Post Traumatic Stress Disorder “PTSD”, while protecting all THC users from negative psychiatric side-effects caused by THC.
Based on successful pre-clinical trial results, CanaQuest is planning to complete human trials and seek regulatory approval for Mentanine®Rx by applying for a Drug Identification Number “DIN number” with the US-based Food and Drug Administration “FDA“ and Health Canada. The Company believes the approval process will be significantly reduced because of the quality of the pre-clinical work and the recent regulatory approvals for other products containing CBD and THC. Regulatory approvals will give CanaQuest the legal right to sell Rx products as approved drugs, Over the Counter, in every pharmacy in the world, where federally permitted.
Mentanine® (Omega-3 compounds + CBD isolate) was produced and successfully tested for quality and safety by third party laboratories in the USA and Canada. Results from pre-clinical trials addressing anxiety, depression, PTSD, and schizophrenia have been scientifically significant. These results also demonstrate reduction of inflammation, which has beneficial implications for pain. Additionally, this can be used to decrease opioid addiction effects and schizophrenia-related symptoms. Mentanine® is tasteless and can be produced as a water-soluble liquid or powder.
Dr. Laviolette stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other approved CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising anti-epilepsy treatment.”
Mentanine® Pre-clinical trials:
Indicated 10 times + the efficacy as compared to CBD molecules alone Reduced Anxiety, Depression, PTSD and Addiction
Showed significant reduction of inflammation, which can be beneficial for pain management.
CanaQuest’s wholly-owned subsidiary, ADC BioMedical Corp, was awarded a cannabis and cannabinoid products, Sales/Purchase, Import/Export license from Health Canada for Medical purposes. CanaQuest is launching Mentanine® soon. The Company is also positioned to launch Mentabinol® upon regulatory approval.
The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science”, presented by the International Trade Council.
CanaQuest has developed an e-commerce website http://www.canaqueststore.com/ to sell directly to its patients as well as through its online distribution channel partners and globally where federally permitted.